Ensysce Biosciences (NASDAQ:ENSC) Announces Earnings Results

Ensysce Biosciences (NASDAQ:ENSC) released its earnings results on Tuesday. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.37, Zacks reports. The firm had revenue of $3.42 million during the quarter, compared to analyst estimates of $0.25 million. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 292.81%.

Ensysce Biosciences Trading Down 10.3 %

NASDAQ ENSC opened at $0.64 on Friday. Ensysce Biosciences has a 12 month low of $0.14 and a 12 month high of $2.06. The stock has a 50-day simple moving average of $0.37 and a 200 day simple moving average of $0.45.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.